Mesenchymal Stem Cells in Homeostasis and Systemic Diseases: Hypothesis, Evidences, and Therapeutic Opportunities
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10347/21197
Files in this item
 |
|  |
Metadata
| Title: | Mesenchymal Stem Cells in Homeostasis and Systemic Diseases: Hypothesis, Evidences, and Therapeutic Opportunities |
| Author: | Vizoso, Francisco J. Eiro, Noemi Costa, Luis Esparza, Paloma Landín Pérez, Mariana Díaz Rodríguez, Patricia Schneider, Jose Pérez Fernández, Román |
| Affiliation: | Universidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicas Universidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica Universidade de Santiago de Compostela. Departamento de Fisioloxía |
| Subject: | Regenerative medicine | Aging diseases | Diabetes | Lupus | Secretome | Conditioned medium | Extracellular vesicles | Exosomes | |
| Date of Issue: | 2019 |
| Publisher: | MDPI |
| Citation: | Vizoso, F.J.; Eiro, N.; Costa, L.; Esparza, P.; Landin, M.; Diaz-Rodriguez, P.; Schneider, J.; Perez-Fernandez, R. Mesenchymal Stem Cells in Homeostasis and Systemic Diseases: Hypothesis, Evidences, and Therapeutic Opportunities. Int. J. Mol. Sci. 2019, 20, 3738 |
| Abstract: | Mesenchymal stem cells (MSCs) are present in all organs and tissues, playing a well-known function in tissue regeneration. However, there is also evidence indicating a broader role of MSCs in tissue homeostasis. In vivo studies have shown MSC paracrine mechanisms displaying proliferative, immunoregulatory, anti-oxidative, or angiogenic activity. In addition, recent studies also demonstrate that depletion and/or dysfunction of MSCs are associated with several systemic diseases, such as lupus, diabetes, psoriasis, and rheumatoid arthritis, as well as with aging and frailty syndrome. In this review, we hypothesize about the role of MSCs as keepers of tissue homeostasis as well as modulators in a variety of inflammatory and degenerative systemic diseases. This scenario opens the possibility for the use of secretome-derived products from MSCs as new therapeutic agents in order to restore tissue homeostasis, instead of the classical paradigm “one disease, one drug”. |
| Publisher version: | https://doi.org/10.3390/ijms20153738 |
| URI: | http://hdl.handle.net/10347/21197 |
| DOI: | 10.3390/ijms20153738 |
| E-ISSN: | 1422-0067 |
| Rights: | © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/) |
Collections
-
- CIMUS-Artigos [188]
- FIS-Artigos [99]
- FTF-Artigos [201]
Share/Send to
 |  |
Cited by
 | ||
 |
Except where otherwise noted, this item's license is described as © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)